1![Why we focus on Lymphoma There are two main types of lymphoma, Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Both are cancers of the lymphatic system and usually present as swelling of the lymph nodes. Al Why we focus on Lymphoma There are two main types of lymphoma, Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Both are cancers of the lymphatic system and usually present as swelling of the lymph nodes. Al](https://www.pdfsearch.io/img/ab2cbcebf13db94687efa22e81f2afeb.jpg) | Add to Reading ListSource URL: www.bci.qmul.ac.uk- Date: 2016-04-04 11:36:10
|
---|
2![KIT FOR MOLECULAR STUDY OF TRANSLOCATION t(11;14) Nº CAT. MAD-003998MDETERMINATIONS) Mantle cell lymphomas are a sub-type of non-Hodgkin’s lymphoma derived from a subset of virgin B-cells localised in the man KIT FOR MOLECULAR STUDY OF TRANSLOCATION t(11;14) Nº CAT. MAD-003998MDETERMINATIONS) Mantle cell lymphomas are a sub-type of non-Hodgkin’s lymphoma derived from a subset of virgin B-cells localised in the man](https://www.pdfsearch.io/img/586df01503103ee4ce004c20af60df5e.jpg) | Add to Reading ListSource URL: www.masterdiagnostica.comLanguage: English - Date: 2014-11-06 04:24:19
|
---|
3![The recent approval of 90Y-labeled Zevalin (IDEC Pharmaceuticals Corp., San Diego, CA) for radioimmunotherapy of non-Hodgkin’s lymphoma has highlighted the regulatory requirement of patient-specific internal radiati The recent approval of 90Y-labeled Zevalin (IDEC Pharmaceuticals Corp., San Diego, CA) for radioimmunotherapy of non-Hodgkin’s lymphoma has highlighted the regulatory requirement of patient-specific internal radiati](https://www.pdfsearch.io/img/f163ca63e5c86e626d31bb0657a74838.jpg) | Add to Reading ListSource URL: www.aapm.orgLanguage: English - Date: 2005-10-18 14:16:03
|
---|
4![SEER Cancer Statistics Review[removed]Table 9.1 Hodgkin Lymphoma Trends in SEER Incidenceab and U.S. Mortalityc Using the Joinpoint Regression Program, [removed]With up to Five Joinpoints, [removed]With up to Three SEER Cancer Statistics Review[removed]Table 9.1 Hodgkin Lymphoma Trends in SEER Incidenceab and U.S. Mortalityc Using the Joinpoint Regression Program, [removed]With up to Five Joinpoints, [removed]With up to Three](https://www.pdfsearch.io/img/60af0cbf8375b236e12531432bbd7552.jpg) | Add to Reading ListSource URL: seer.cancer.govLanguage: English - Date: 2014-12-16 11:15:02
|
---|
5![Oncologic Drugs Advisory Committee Meeting Briefing Document Pixantrone dimaleate (BBR[removed]Injection for the treatment of patients with relapsed or refractory aggressive Non-Hodgkin’s Lymphoma who have received 2 or Oncologic Drugs Advisory Committee Meeting Briefing Document Pixantrone dimaleate (BBR[removed]Injection for the treatment of patients with relapsed or refractory aggressive Non-Hodgkin’s Lymphoma who have received 2 or](https://www.pdfsearch.io/img/552d60ec7599393b8d6eed20a1ff4d99.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
6![NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Hodgkin’s Lymphomas NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Hodgkin’s Lymphomas](https://www.pdfsearch.io/img/dae2c323e7cc846064d5b2059b1e86d7.jpg) | Add to Reading ListSource URL: cutaneouslymphoma.stanford.eduLanguage: English - Date: 2014-01-17 11:32:03
|
---|